癌症研究
免疫检查点
免疫系统
医学
免疫疗法
结直肠癌
肿瘤微环境
癌症
STAT1
癌症免疫疗法
免疫学
癌细胞
STAT蛋白
T细胞
主要组织相容性复合体
胞苷脱氨酶
CD8型
抗原
细胞
肺癌
MHC I级
生物
抗体
封锁
重编程
PD-L1
信号转导
作者
Siqi Chen,Qishan Liu,Shubiao Ye,Jing Yu,Yongxin Xie,Yuhai Yuan,Jianning Song,Yaqing Du,Min Li,Xueli Zhang,Yanping Ma,林振森,Yu Zhang,Xin‐Yuan Guan,Guiwei He,Chen Jiang,Xiaona Fang,Xiaosheng He,Lei Li,Ping Lan
标识
DOI:10.1126/scitranslmed.aed2106
摘要
Loss of major histocompatibility complex class I (MHC-I) antigen presentation in tumor cells drives immune evasion and resistance to immune checkpoint blockade (ICB) in colorectal cancer (CRC). To identify therapeutic targets reversing this, we conducted fluorescence-activated cell sorting–based CRISPR activation screens using a druggable genome library and identified folate receptor α (FOLR1) as a top negative regulator. FOLR1 was heterogeneously expressed in CRC tumors but undetectable in adjacent normal tissues. High expression of FOLR1 predicted a poor ICB response, enhanced cancer stemness, and unfavorable patient outcomes. Functional assays showed that FOLR1 promoted CRC stemness–associated properties and fostered an immunosuppressive tumor microenvironment (TME) with impaired CD8 + T cell infiltration and cytotoxicity, thereby driving tumor progression. Proteomic analyses revealed that FOLR1 stabilized the lactyltransferase AARS1 (alanyl-tRNA synthetase 1), which lactylated signal transducer and activator of transcription 1 (STAT1) at lysine-193 (K193), facilitating its interaction with TCPTP (T cell protein-tyrosine phosphatase) and inducing STAT1 dephosphorylation at tyrosine-701. Consequently, impaired STAT1 signaling down-regulated MHC-I and up-regulated MYC proto-oncogene protein (c-MYC), facilitating evasion of T cell surveillance and enhancing cancer stemness. The anti-FOLR1 antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) exhibited potent activity against FOLR1-positive CRC cells, reprogramming the TME to an immune-active status. Combining IMGN853 with anti–PD-1 (programmed cell death protein–1) therapy boosted antitumor immunity, sensitized tumors to immunotherapy, and induced robust tumor regression in vivo. Our findings support anti-FOLR1 ADC as a clinically actionable approach to overcome immune evasion and unlock immunotherapy efficacy in CRC.
科研通智能强力驱动
Strongly Powered by AbleSci AI